In a slew of recent blank-check deals, another digital health startup is looking to go public. Roman Health Ventures, the parent company of direct-to-consumer health startup Ro, is reportedly in talks to go public through a merger with a special-purpose acquisition company (SPAC), according to Reuters.
Citing anonymous sources, Reuters reported that the deal could value Ro at more than $4 billion. Last year, a $200 million funding round led by General Catalyst valued the startup at $1.5 billion.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It’s not clear which company is behind the deal. SPACs are companies with no operations, that go public with the goal of acquiring a private company, which then becomes publicly traded after the merger.
Earlier last month, Ro’s rival, Hims & Hers, began trading on the New York Stock Exchange after merging with a subsidiary of Oaktree Capital Management. The deal valued the startup at $1.6 billion.
Similar to Hims & Hers, New York-based Ro has two health and wellness sites targeted at men and women: Roman and Rory. Both offer prescription and over-the-counter products for common conditions, such as dandruff, herpes or allergies.
Ro also owns a Zero, which offers smoking cessation products. All of its brands ship medications to customers after a brief online consultation.
A number of other digital health startups are also plotting their own blank-check deals. Talkspace, which lets users text a therapist, is planning a blank-check deal that would value the company at $1.4 billion, the company shared earlier this month. And Sharecare, which built a wellness app with features like step tracking, is reportedly looking at a deal that would value the startup at $4 billion.